A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Brian G. Feagan(Western University), Anders Olson(University of California, Los Angeles), Suzanne Travers, B E Sands(Icahn School of Medicine at Mount Sinai), D. H. Present, Jewel Johanns(Johnson & Johnson (United States))
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k